Publications by authors named "B Roch"
Patients with stage III NSCLC with N2 lymph node involvement carry a complex and diverse disease entity. Challenges persist in the areas of diagnosis, staging, multimodal management, and the determination of surgical indications and resectability criteria. Therefore, this review focuses on the latest updates in N2 disease staging and its prognostic and treatment implications.
View Article and Find Full Text PDFWe examined from a large exploratory study cohort of COVID-19 patients ( = 549) a validated panel of neutrophil extracellular traps (NETs) markers in different categories of disease severity. Neutrophil elastase (NE), myeloperoxidase (MPO), and circulating nuclear DNA (cir-nDNA) levels in plasma were seen to gradually and significantly ( < 0.0001) increase with the disease severity: mild (3.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the relationship between the number of brain metastases (BM) and total tumor burden (TTB) with overall survival (OS) in patients with non-small cell lung cancer (NSCLC) who underwent surgery for brain metastases.
- A total of 184 patients were analyzed, revealing that the median OS was 19.2 months, with younger patients and those with fewer metastases and lower TTB having improved survival rates.
- Key findings suggest that factors like single brain metastasis and additional treatments, such as radiation and targeted therapy, significantly correlate with better patient outcomes post-surgery.
Background: Research on circulating mitochondrial DNA (cir-mtDNA) based diagnostic is insufficient, as to its function, origin, structural features, and particularly its standardization of isolation. To date, plasma preparation performed in previous studies do not take into consideration the potential bias resulting from the release of mitochondria by activated platelets.
Methods: To tackle this, we compared the mtDNA amount determined by a standard plasma preparation method or a method optimally avoiding platelet activation.
Background: Patients with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary resistance) or after durable benefit (secondary resistance). The cancer vaccine OSE2101 may invigorate antitumor-specific immune responses after ICB failure. The objective of ATALANTE-1 was to evaluate its efficacy and safety in these patients.
View Article and Find Full Text PDF